The third quarter report of multinational pharmaceutical companies: eye disease drug market competition is fierce
-
Last Update: 2016-11-01
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Xinkangjie 2016-11-1 as of October 26, 2016, Johnson & Johnson, Roche, Lilly, Novartis, MSD, Bayer and other pharmaceutical companies issued three quarterly reports, and the editor briefly reviewed some key pharmaceutical market performance of these multinational pharmaceutical companies Note: the euro is calculated at the unified exchange rate of 1.12 Eye disease drug market: Bayer's eylea, especially in the U.S market, has an absolute advantage In the second quarter of 2016, sales of eyla in the U.S region exceeded the global sales of Novartis Lucentis In China, Lucentis's life is not easy Facing the strong competition of Longmu, Lucentis chose to reduce the price by 2600 yuan to 7200 yuan, only slightly higher than the 6800 yuan of Longmu Lucentis still does not have a cost advantage given the lower frequency of use of Ramulus With the launch of phase III clinical treatment of Lamu in the United States, the market competition of ophthalmic drugs targeted by VEGF is more complicated Original address: http://news.pharmnet.com.cn/news/2016/11/01/456813.html
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
